Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

References

• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• CookMNGirmanCJSteinPPAlexanderCMInitial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary careDiabet Med200724435035817335466
   PubMed Web of Science ®Google Scholar
• ForetzMViolletBTherapy: Metformin takes a new route to clinical efficacyNat Rev Endocrinol201511739039226032104
   PubMed Web of Science ®Google Scholar
• MillerRAChuQXieJForetzMViolletBBirnbaumMJBiguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMPNature2013494743625626023292513
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• DeaconCFAhrenBHolstJJInhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes?Expert Opin Investig Drugs200413910911102
   PubMed Web of Science ®Google Scholar
• PatelNPPughMEGoldbergSEigerGHyperinsulinemic euglycemia therapy for verapamil poisoning: a reviewAm J Crit Care200716549850317724247
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• KountzDThe dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groupsAdv Ther201330121067108524287690
   PubMed Web of Science ®Google Scholar
• KimTELimKSParkMKEvaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human studyClin Ther20123491986199822943970
   PubMed Web of Science ®Google Scholar
• JungCHParkCYAhnKJA randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exerciseDiabetes Metab Res Rev201531329530625362864
   PubMed Web of Science ®Google Scholar
• Goldman-LevineJDBeyond metformin: initiating combination therapy in patients with type 2 diabetes mellitusPharmacotherapy20113112 Suppl44S53S22122222
   PubMed Web of Science ®Google Scholar
• YokohHKobayashiKSatoYEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trialJ Diabetes Investig201562182191
   PubMed Web of Science ®Google Scholar
• GuNParkMKKimTEMultiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersDrug Des Devel Ther2014817091721
   PubMed Web of Science ®Google Scholar
• ShinDChoYMLeeSPharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjectsClin Drug Investig2014346383393
   PubMed Web of Science ®Google Scholar
• LiuJJChengXHFuLLC-MS based assay method for DPP-IV inhibitor screening and substrate discoveryAnal Methods20124617971805
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for Industry, Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labelling Recommendations22012
   Google Scholar
• CullenELiaoJLukacskoPNiecestroRFriedhoffLPharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteersBiopharm Drug Dispos200425626126315334625
   PubMed Web of Science ®Google Scholar
• ErnsbergerPKoletskyRJThe glucose tolerance test as a laboratory tool with clinical implicationsChackrewarthySGlucose ToleranceRijeka, CroatiaInTech2012314
   Google Scholar
• KimHJKwakWYMinJPDiscovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesBioorg Med Chem Lett201121123809381221570283
   PubMed Web of Science ®Google Scholar
• GrahamGGPuntJAroraMClinical pharmacokinetics of metforminClin Pharmacokinet2011502819821241070
   PubMed Web of Science ®Google Scholar
• Graefe-ModyEUPadulaSRingAWithopfBDugiKAEvaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjectsCurr Med Res Opin20092581963197219552619
   PubMed Web of Science ®Google Scholar
• MigoyaEMBergeronRMillerJLDipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1Clin Pharmacol Ther201088680180821048706
   PubMed Web of Science ®Google Scholar
• QuesadaITuduriERipollCNadalAPhysiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetesJ Endocrinol2008199151918669612
   PubMed Web of Science ®Google Scholar
• BytzerPTalleyNJJonesMPHorowitzMOral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitusAliment Pharmacol Ther200115113714211136287
   PubMed Web of Science ®Google Scholar